#88: Jia En Chin, Shirley Lu, Thijs Spoor: New Opportunities for Biotechs in China

What are the opportunities for Biotechs in the Chinese Market? Get answers to this question in this podcast with the BFC Group.

⭐We are talking about
The BFC Group
The Capital Market Landscape in China
Deal Structuring in China
Clinical Strategies for China
Why Affordability and Accessibility of new drugs matter in China

⭐About BFC Group:
BFC Group is a China-based investment banking firm with a focus on healthcare M&A, licensing, and financing.  We work with leading healthcare companies in the US, Europe, and Asia.  With first-hand operational experience in both the US and China, we have a deep understanding of the challenges our clients face when establishing or expanding their companies’ presence outside of their home market. 

⭐ EPISODE Links:
Jia En Chin
Thijs Spoor
Shirley Lu:
BFC Group:
Youtube Presentation best viewed on Youtube

🎤 Quotes:
(26:04) “China is now the second largest pharma market in the world, Japan being third” 
(31:11) “Many of our clients are still in Clinical Phase I, when they come to China”
(33:29) “The China Market really rewards innovation in antibiotic research.”
(48:30) “China takes care to make therapeutics accessible and affordable for the population”
(51:24) “China's growing middle class wants to improve their quality of life.”
(59:45) “Finding the right partner for a Go-To-China-Strategy is key to success. Otherwise, it can become very costly and might damage the asset.”
(01:00:38) "... you want a personal connection, you want to educate and not sell..."
(01:16:30) “In Q1/2022 18 new drugs were approved in China, 12 of them came from The West.”

🕛 Timestamps:
(00:00) Introductions
(13:00) BFC Group Introduction to the Chinese Market
(15:45) Capital Market Landscape in China
(18:30) China Investment and Financing Trend
(21:43) Licensing Deal Trends in China
(25:00) Opportunities for Biotechs in China
(25:45) The biggest Pharma Markets and Innovators  
(30:00) Deal-Focus of Chinese Pharma Companies
(32:00) The Therapeutic Focus in China in 2022
(33:41) Antibiotics Research in China
(36:40) The Major Player in Infectious Diseases and Cancer on the Chinese Market 
(38:00) Market Potential in China for Chronic Diseases
(39:55) The KBP Business Case
(40:48) Patent Strategies for the Chinese Market
(44:24) Important Points for Preparing a Market Entry in China
(48:00) Price Dynamics and Reimbursement in China
(49:30) Why Affordability and Accessibility Matters in China
(50:30) The Necessary Data Packages for Market Entry in China
(53:00) Clinical Strategies for Market Entry in China
(56:30) Is a multi-center approach across several markets feasible in later-stage clinical trials?
(01:01:30) Similarities and Differences in Culture, Communication
(01:08:15) The Right approach for a Go-To-China Strategy
(01:13:22) The Availability of Capital on Private and Public Markets for Foreign Companies